Oncology Central

Overcoming immune system evasion by personalized immunotherapy

0

With the US FDA’s approval of the first cancer vaccine for prostate cancer [1] and immune checkpoint blockade therapy against CTLA-4 for melanoma [2], the complex interaction between antitumor immune responses and tumor immune evasion is being intensely scrutinized. Despite a number of exciting preclinical studies and clinical research, most novel immunotherapies have demonstrated limited efficacy in early-phase clinical trials. The reason for this is multifactorial.

To view restricted content, please:
Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.